Methotrexate (MTX) is a chemotherapeutic agent that is used to treat a host of malignancies. But recently, MTX has also been used as a therapeutic agent for chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. However, MTX is an antimetabolite that affects rapidly dividing normal cells such as oral mucosal epithelial cells, gastrointestinal epithelial cells, and bone marrow cells-which explains why oral mucositis is often an initial manifestation of MTX toxicity. Because oral lesions are frequently initially presented in dental clinics, dentists should consider the possibility of adverse drug reactions in the differential diagnoses of oral lesions through a meticulous collection of patients' medical histories. In this report, we examine patients who suffered from oral ulcerative lesions upon diagnosis of MTX-induced oral mucositis. Then, we suggest approaches for the diagnosis and treatment of MTX-induced oral mucositis through a review of literature.
INTRODUCTION
Since its introduction over 50 years ago as a treatment for childhood acute lymphocytic leukemia, methotrexate (MTX) has proved useful as a chemotherapeutic agent for various malignancies including hematological and trophoblastic malignancies, osteosarcomas, bladder cancer, head and neck cancer, lung cancer, and breast cancer. 1) MTX is also widely used as a therapeutic agent for chronic inflammatory disorders such as rheumatoid arthritis (RA), 2) psoriasis, 3) systemic lupus erythematosus, 4) granulomatosis with polyangiitis (Wegener's), 5) Crohn disease 6) and in the prevention of graft-versus-host disease. 7) MTX is a folic acid (FA) antagonist that interferes reversibly with the action of several key enzymes including dihydrofolate-reductase, thymidilate synthetase and amino-imidazolecarboxamide ribosyl-5-phosphate (AICAR) transformylase in the folate pathway. 8) These enzymes are requisite for the synthesis of purines and pyrimidines. MTX's inhibition of the folate pathway interferences with nucleotide synthesis and, consequently, inhibits the cell cycle.
The exact mechanism of MTX in immunological disorders has not been fully elucidated. However, it is known that intracellular accumulation of AICAR and homocysteine induces the release of adenosine, which has anti-inflammatory effects and immunosuppressive effects modulated by an increase in cyclic adenosine monophosphate. 9, 10) MTX can also modulate the function of immune cells and reduce the production of several cytokines (interleukins, tumor-necrosis factor, and interferon). The patient's symptoms were getting progressively worse, so she was referred to a rheumatologist for MTX toxicity.
She was advised to not take any more MTX and was prescribed a once-daily dose of 1 mg of FA. The definitive diagnosis was oral mucositis due to MTX toxicity. Upon review two weeks post-MTX cessation, the patient's symptoms had abated and the ulceration was recovering normally (Fig. 2) . Laboratory test results were as follows:
RBC, 3.71; hemoglobin, 12.1; Hct, 36.9. The remaining results, including platelet count and folate levels, were within the normal range. It is clear that pre-existing folate deficiency increases MTX toxicity in the oral mucosa.
Case 2
A 71-year-old-female patient was referred from the de- She has taken 10 mg of MTX once weekly for two monthsher medical history revealed that she had previously taken (Fig. 4 ).
Case 3
A 68-year-old female patient presented with severe stomatitis and the patient was unable to eat for three weeks due to her symptoms. The patient could not pinpoint any specific reason for her symptoms besides the fact that she took stomach ulcer medication three weeks ago. and oral mucosa with bleeding tendencies (Fig. 5) . 
DISCUSSION
In a previous study, oral mucositis was reported in patients who were prescribed low-dose MTX but ultimately overdosed either due to prescription error or patients' confusion regarding its once-weekly regime. 11, 12) In this case study, however, MTX toxicity seems to have been elevated by several factors such as deficiency of FA, 13) reduced renal function, 14) and drug interaction, 13) even if the dosage of MTX does not change. In addition, while oral mucositis has commonly been known to appear as an initial sign of MTX toxicity, it actually develops relatively late after longterm MTX administration in our cases. MTX toxicity can also prevent healing in previously existing lesions, such as traumatic ulcers. 15) The oral lesions that had lasted for more than a month were resolved within 2 to 3 weeks after discontinuation or dose reduction of MTX. Oral lesions that do not respond well to treatment require a differential diagnosis for toxicity of the drug through the careful collection of patient medical history and clinical examinations (including laboratory tests).
MTX is generally administered at a weekly dose of 5 to 25 mg for the management of chronic inflammatory disorders. 16) The toxicity of MTX is affected by administration of the dosage, the duration of the dosage, the age of the patient, and his/her renal and hepatic function. Potential risk factors for MTX toxicity include pre-existing folate deficiency, hypoalbuminemia, and interaction with other drugs.
13)
For example, aspirin and other nonsteroidal antiinflammatory drugs displace MTX from protein and reduce renal clearance, increasing blood levels and toxicity. 1) Concurrent use of proton-pump-inhibitors can also be considered a potential risk factor, but is only reported in cancer patients receiving high doses of MTX.
Thirty percent to eighty percent of patients on low-dose MTX experienced adverse effects due to MTX toxicity, 17) and 5% to 35% of these patients stopped taking MTX as a result. 18) However, more severe adverse effects can be recovered relatively easily through administration of folate 19) and/ or the dose reduction or cessation of MTX. 18 Oral mucositis is a common concern for many patients, and dentists are often the first doctors to find out about the condition and treat it. Because oral mucositis may be an early sign of a more foreboding condition, early recognition may help in ensuring effective treatment. It is important to perform a thorough evaluation of the patient with oral mucositis and to thus determine the underlying cause of the patient's oral mucositis so that appropriate treatment can be implemented in a timely manner. Finding the underlying causes can be done through careful questioning of the patient's medical history and screenings/laboratory tests.
Dentists should have the ability to determine these underlying causes and make a differential diagnosis with similar diseases. Dentists also must be aware that oral mucositis can be induced by drug toxicity. Furthermore, if systemic problems are suspected, referral of the patient to the appropriate department of medicine is highly important.
